Epidemiology, risk factors, and treatment of chronic migraine: A focus on topiramate

Stephen Silberstein, Hans Christoph Diener, Richard Lipton, Peter Goadsby, David William Dodick, Genaro Bussone, Fred Freitag, Susan Schwalen, Steven Ascher, Jacqueline Morein, Steven Greenberg, David Biondi, Joseph Hulihan

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The term chronic daily headache refers to a heterogeneous group of headache disorders characterized by a frequency of headaches on ≥15 days per month. Chronic migraine is a subtype of chronic daily headache. The prevalence of chronic migraine is ∼1%. Baseline attack frequency and acute medication overuse have been identified as potential risk factors for the progression of migraine from an episodic disorder to a chronic condition. There is an unmet patient need for effective and safe treatments for patients with chronic migraine, but data from rigorous controlled trials are limited. Previous studies have demonstrated that topiramate is an effective and safe preventive treatment for episodic migraine. In addition, pilot studies have suggested the utility of topiramate for the prevention of chronic migraine. Two randomized, double-blind, placebo-controlled, multicenter trials investigating the efficacy and safety of topiramate in the treatment of patients with chronic migraine have recently been completed. This review presents comparative data from these 2 clinical trials, which suggest that topiramate at a dose of 100 mg daily is effective and generally well tolerated in chronic migraine.

Original languageEnglish (US)
Pages (from-to)1087-1095
Number of pages9
JournalHeadache
Volume48
Issue number7
DOIs
StatePublished - Jul 2008

Fingerprint

Migraine Disorders
Epidemiology
Headache Disorders
Therapeutics
topiramate
Multicenter Studies
Headache
Placebos
Clinical Trials
Safety

Keywords

  • Chronic migraine
  • Topiramate

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Silberstein, S., Diener, H. C., Lipton, R., Goadsby, P., Dodick, D. W., Bussone, G., ... Hulihan, J. (2008). Epidemiology, risk factors, and treatment of chronic migraine: A focus on topiramate. Headache, 48(7), 1087-1095. https://doi.org/10.1111/j.1526-4610.2008.01185.x

Epidemiology, risk factors, and treatment of chronic migraine : A focus on topiramate. / Silberstein, Stephen; Diener, Hans Christoph; Lipton, Richard; Goadsby, Peter; Dodick, David William; Bussone, Genaro; Freitag, Fred; Schwalen, Susan; Ascher, Steven; Morein, Jacqueline; Greenberg, Steven; Biondi, David; Hulihan, Joseph.

In: Headache, Vol. 48, No. 7, 07.2008, p. 1087-1095.

Research output: Contribution to journalArticle

Silberstein, S, Diener, HC, Lipton, R, Goadsby, P, Dodick, DW, Bussone, G, Freitag, F, Schwalen, S, Ascher, S, Morein, J, Greenberg, S, Biondi, D & Hulihan, J 2008, 'Epidemiology, risk factors, and treatment of chronic migraine: A focus on topiramate', Headache, vol. 48, no. 7, pp. 1087-1095. https://doi.org/10.1111/j.1526-4610.2008.01185.x
Silberstein, Stephen ; Diener, Hans Christoph ; Lipton, Richard ; Goadsby, Peter ; Dodick, David William ; Bussone, Genaro ; Freitag, Fred ; Schwalen, Susan ; Ascher, Steven ; Morein, Jacqueline ; Greenberg, Steven ; Biondi, David ; Hulihan, Joseph. / Epidemiology, risk factors, and treatment of chronic migraine : A focus on topiramate. In: Headache. 2008 ; Vol. 48, No. 7. pp. 1087-1095.
@article{d4c57a0d1be14510b523e101846aaf2f,
title = "Epidemiology, risk factors, and treatment of chronic migraine: A focus on topiramate",
abstract = "The term chronic daily headache refers to a heterogeneous group of headache disorders characterized by a frequency of headaches on ≥15 days per month. Chronic migraine is a subtype of chronic daily headache. The prevalence of chronic migraine is ∼1{\%}. Baseline attack frequency and acute medication overuse have been identified as potential risk factors for the progression of migraine from an episodic disorder to a chronic condition. There is an unmet patient need for effective and safe treatments for patients with chronic migraine, but data from rigorous controlled trials are limited. Previous studies have demonstrated that topiramate is an effective and safe preventive treatment for episodic migraine. In addition, pilot studies have suggested the utility of topiramate for the prevention of chronic migraine. Two randomized, double-blind, placebo-controlled, multicenter trials investigating the efficacy and safety of topiramate in the treatment of patients with chronic migraine have recently been completed. This review presents comparative data from these 2 clinical trials, which suggest that topiramate at a dose of 100 mg daily is effective and generally well tolerated in chronic migraine.",
keywords = "Chronic migraine, Topiramate",
author = "Stephen Silberstein and Diener, {Hans Christoph} and Richard Lipton and Peter Goadsby and Dodick, {David William} and Genaro Bussone and Fred Freitag and Susan Schwalen and Steven Ascher and Jacqueline Morein and Steven Greenberg and David Biondi and Joseph Hulihan",
year = "2008",
month = "7",
doi = "10.1111/j.1526-4610.2008.01185.x",
language = "English (US)",
volume = "48",
pages = "1087--1095",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Epidemiology, risk factors, and treatment of chronic migraine

T2 - A focus on topiramate

AU - Silberstein, Stephen

AU - Diener, Hans Christoph

AU - Lipton, Richard

AU - Goadsby, Peter

AU - Dodick, David William

AU - Bussone, Genaro

AU - Freitag, Fred

AU - Schwalen, Susan

AU - Ascher, Steven

AU - Morein, Jacqueline

AU - Greenberg, Steven

AU - Biondi, David

AU - Hulihan, Joseph

PY - 2008/7

Y1 - 2008/7

N2 - The term chronic daily headache refers to a heterogeneous group of headache disorders characterized by a frequency of headaches on ≥15 days per month. Chronic migraine is a subtype of chronic daily headache. The prevalence of chronic migraine is ∼1%. Baseline attack frequency and acute medication overuse have been identified as potential risk factors for the progression of migraine from an episodic disorder to a chronic condition. There is an unmet patient need for effective and safe treatments for patients with chronic migraine, but data from rigorous controlled trials are limited. Previous studies have demonstrated that topiramate is an effective and safe preventive treatment for episodic migraine. In addition, pilot studies have suggested the utility of topiramate for the prevention of chronic migraine. Two randomized, double-blind, placebo-controlled, multicenter trials investigating the efficacy and safety of topiramate in the treatment of patients with chronic migraine have recently been completed. This review presents comparative data from these 2 clinical trials, which suggest that topiramate at a dose of 100 mg daily is effective and generally well tolerated in chronic migraine.

AB - The term chronic daily headache refers to a heterogeneous group of headache disorders characterized by a frequency of headaches on ≥15 days per month. Chronic migraine is a subtype of chronic daily headache. The prevalence of chronic migraine is ∼1%. Baseline attack frequency and acute medication overuse have been identified as potential risk factors for the progression of migraine from an episodic disorder to a chronic condition. There is an unmet patient need for effective and safe treatments for patients with chronic migraine, but data from rigorous controlled trials are limited. Previous studies have demonstrated that topiramate is an effective and safe preventive treatment for episodic migraine. In addition, pilot studies have suggested the utility of topiramate for the prevention of chronic migraine. Two randomized, double-blind, placebo-controlled, multicenter trials investigating the efficacy and safety of topiramate in the treatment of patients with chronic migraine have recently been completed. This review presents comparative data from these 2 clinical trials, which suggest that topiramate at a dose of 100 mg daily is effective and generally well tolerated in chronic migraine.

KW - Chronic migraine

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=46749137929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46749137929&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4610.2008.01185.x

DO - 10.1111/j.1526-4610.2008.01185.x

M3 - Article

C2 - 18687081

AN - SCOPUS:46749137929

VL - 48

SP - 1087

EP - 1095

JO - Headache

JF - Headache

SN - 0017-8748

IS - 7

ER -